Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
GlaxoSmithKline is boosting its cancer therapy pipeline by paying Merck KGaA about $340 million to jointly develop and commercialize a cancer immunotherapy from the German firm. The experimental therapy, bintrafusp alfa, is a fusion protein that targets two pathways used by cancer cells to suppress the immune system: transforming growth factor-β and programmed cell death ligand-1 (PD-L1). Anti-PD-L1 antibodies are part of an increasingly lucrative class of cancer drugs that firms are looking to combine with other therapies. Merck could earn up to $3.9 billion in future milestone payments.
This article has been sent to the following recipient: